Angiopeptin - An immunological review

Transplant Immunology

Volumn 4, Issue 2, 1996, Pages 99-104

  Motomura, Noboru ^a   Foegh, Marie L ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; DRUG RECEPTOR; HYPOTHALAMUS RELEASE INHIBITING FACTOR;

ALLOGRAFT; ANIMAL MODEL; BIOCHEMISTRY; DRUG MECHANISM; DRUG STRUCTURE; HEART TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; REVIEW; SIGNAL TRANSDUCTION;

EID: 0030175061     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(96)80002-5     Document Type: Review

References (72)

1. Billingham M.E. Graft coronary disease: the lesions and the patients. Transplant Proc. 4:1989;3665-3666.
2. Foegh M.L. Chronic rejection - graft atherosclerosis. Transplant Proc. 22:1990;119-122.
3. Scheidt WV, Ziegler U, Kemkes BM, et al. Coronary angioplasties after heart transplantation [Abstract]. Eur Heart J. 8:1990;322-22.
4. Billingham M.E. Cardiac transplant atherosclerosis. Transplant Proc. 19:1987;19-25.
5. Foegh M.L. Accelerated cardiac transplant atherosclerosis/chronic rejection in rabbits: inhibition by angiopeptin. Transplant Proc. 25:1993;2095-2097.
6. Foegh M.L, Virmani R. Molecular biology of intimal proliferation. Ann Cardiac Surg. 1994;53-65.
7. Kuwahara M, Jacobsson J, Kuwahara M, Kagan E, Ramwell P.W, Foegh M.L. Coronary artery ultrastructural changes in cardiac transplant atherosclerosis in the rabbit. Transplantation. 52:1991;759-765.
8. Ewel C.H, Foegh M.L. Chronic graft rejection: accelerated transplant arteriosclerosis. Immunol Rev. 134:1993;21-31.
9. Pearse A, Polak JM, Bloom S.R. The newer gut hormones. Cellular sources, physiology, pathology and clinical aspects. Gastroenterology. 72:1977;746-761.
10. Taylor J.E, Bogden A.E, Moreau J.P, Coy D.H. In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue. Biochem Biophys Res Commun. 153:1988;81-86.
11. Heiman M.L, Murphy W.A, Coy D.H. Differential binding of somatostatin agonist to somatostatin receptors in brain and adenohypophysis. Neuroendocrinology. 45:1987;429-436.
12. Murphy W, Lance V, Moreau S. Inhibition of rat prostate tumor growth by an octapeptide analog of somatostatin. Life Sci. 40:1987;2515-2522.
13. Bogden A, Taylor J, Moreau J.P, Coy D.H, Le Page D.J. Response of human lung tumor xenografts to treatment with a somatostatin analogue. Cancer Res. 50:1990;4360-4365.
14. Lundergan C, Foegh M.L, Vargas R, et al. Inhibition of myointimal proliferation of the rat carotid artery by the peptides, angiopeptin and BIM 23034. Atherosclerosis. 80:1989;49-55.
15. Foegh M.L. Angiopeptin: a treatment for accelerated myointimal hyperplasia? J Heart Lung Transplant. 11:1992;S28-S31.
16. Cathapermal S.S, Foegh M.L, Rau C, Ramwell P.W. Disposition and tissue distribution of angiopeptin in the rat. Drug Metab Dispos. 19:1991;735-739.
17. 131I iodinated drug analog. Pharm Res. 80:1985;80-83.
18. Bake J.R.J, Kemmenenoe B.H, McMartin C, Peters G.E. Pharmacokinetics, distribution and elimination of a synthetic octapeptide analogue of somatostatin in the rat. Regul Pept. 9:1984;213-216.
19. Peters G.E. Distribution and metabolism of exogeneous somatostatin in the rat. Regul Pept. 3:1982;361-369.
20. McMartin C, Purdon G.E. Early fate of somatostatin in the circulation of the rat after intravenous injection. J Endocrinol. 77:1987;67-74.
21. Lemaire M, Azria M, Dannecker R, Marbach P, Schweitzer A, Maurer G. Dispositions of sandostatin, a new synthetic somatostatin analogue, in rats. Drug Metab Dispos. 17:1989;699-703.
22. Kuhn JM, Basin C, Baudoin C, et al. Influence de la dose et des monalités d'administration du BIM 23014 sur la sécrétion d'hormone de croissance de l'acromégale. Ann Endocrinol. 53:1992;208-214.
23. Kuhn JM, Basin C, Mollard M, et al. Pharmacokinetic study and effects on growth hormone secretion in healthy volunteers of the new somatostatin analogue BIM 23014. Eur J Clin Pharmacol. 45:1993;73-77.
24. Kuhn JM, Legrand A, Ruiz JM, et al. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br J Clin Pharmacol. 38:1994;213-219.
25. Meiser BM, Wolf S, Devens C.H, et al. Continuous infusion of angiopeptin significantly reduces accelerated graft vessel disease induced by FK 506 in a rat heart allograft model. Transplant Proc. 24:1992;1671-1672.
26. Foegh M.L, Khirabadi B.S, Chambers E, Amamoo S, Ramwell P.W. Inhibition of coronary artery transplant atherosclerosis in rabbits with angiopeptin, an octapeptide. Atherosclerosis. 78:1989;229-236.
27. Lou H, Kodama T, Maurice P.F, et al. Angiopeptin suppresses T-lymphocyte, macrophage infiltration and MHC class II antigen in the coronary artery following cardiac transplantation. Circulation. 92:1995;I-704. (suppl I).
28. Foegh M.L, Khirabadi B.S, Chambers E, Ramwell P.W. Peptide inhibition of accelerated transplant atherosclerosis. Transplant Proc. 21:1989;3674-3676.
29. Pawlikowski M, Stepien H, Kunert-Radek J, Schally AV. Effect of somatostatin on the proliferation of mouse spleen lymphocytes in vitro. Biochem Biophys Res Commun. 129:1985;52-55.
30. Fellström B, Dimeny E, Foegh M.L, Larsson E, Wanders A, Tufvesson G. Accelerated atherosclerosis in heart transplants in the rat simulating chronic vascular rejection: effects of prostacyclin and angiopeptin. Transplant Proc. 23:1991;525-528.
31. Mennander A, Tiisaka S, Halttunen J, Yilmaz S, Paavonen T, Häyry P. Chronic rejection in rat aortic allografts. An experimental model for transplant arteriosclerosis. Arterioscler Thromb. 11:1991;671-680.
32. Motomura N, Imakita M, Yutani C, et al. Histologic modification by cryopreservation in rat aortic allografts. Ann Thorac Surg. 60:1995;S168-S171.
33. Gohra H, McDonald T.O, Verrier E.D, Aziz S. Endothelial loss and regeneration in a model of transplant arteriosclerosis. Transplantation. 60:1995;96-102.
34. Mennander A, Räisänen A, Paavonen T, Häyry P. Chronic rejection in the rat aortic allograft. V. Mechanism of the angiopeptin (BIM23014C) effect on the generation of allograft arteriosclerosis. Transplantation. 55:1993;124-128.
35. Akyürek M.L, Wanders S, Aurivillius M, Larsson E, Funa K, Fellström BC. Effects of angiopeptin on transplant arteriosclerosis in the rat. Transplant Int. 8:1995;103-110.
36. Bauters C, Belle EV, Wernert N, et al. Angiopeptin inhibits oncogene induction in rabbit aorta after balloon denudation. Circulation. 89:1994;2327-2331.
37. Sreedharem S.P, Kodama K.T, Peterson K.E, Goetzl E.J. Distinct subsets of somatostatin receptors on cultured human lymphocytes. J Biol Chem. 264:1989;949-957.
38. Scicchitano R, Dazin P, Bienenstock J, Payan D.G, Stanisz AM. Distribution of somatostatin receptors on murine spleen and peyer's patch T and B lymphocytes. Brain Behav Immun. 1:1987;173-184.
39. Bhathena S.J, Louie J, Schechter G.P, Redman R.S, Whol L, Recant L. Identification of human mononuclear leukocytes bearing receptors for somatostatin and glucagon. Diabetes. 30:1981;127-131.
40. Nakamura H, Koike T, Hiruma K, Sato T, Tomioka H, Yoshida S. Identification of lymphoid cell lines bearing receptors for somatostatin. Immunology. 62:1987;655-658.
41. Payan D.G, Goetzl E.J. Modulation of lymphocyte function by sensory neuropeptides. J Immunol. 135:1985;738s-786s. (suppl 2).
42. Stanisz SM, Befus D.A, Bienenstock J. Differential effects of vasoactive intestinal peptide, substance P and somatostatin on immunoglobulin synthesis and proliferation by lymphocytes from Peyer's patches, mesenteric lymph nodes and spleen. J Immunol. 136:1986;152-156.
43. Agro A, Padol I, Stanisz AM. Immunomodulatory activities of the somatostatin analogue BIM 23014c: effects on murine lymphocyte proliferation and natural killer activity. Regul Pept. 32:1991;129-139.
44. Jacobs K.H, Aktories K, Schultz G. A nucleotide regulatory site for somatostatin inhibition of adenylyl cyclase in S49 lymphoma cells. Nature. 303:1983;177-178.
45. Law S, Manning D, Reisine T. Identification of the subunits of GTP binding proteins coupled to somatostatin receptors. J Biol Chem. 266:1991;17885-17897.
46. 1 pituitary cell membranes. Endocrinology. 114:1984;1784-1790.
47. Bruns C, Weckbecker G, Raulf F, et al. Molecular pharmacology of somatostatin-receptor subtypes. Ann NY Acad Sci. 733:1994;138-146.
48. Raynor K, Murphy W, Coy D, et al. Cloned somatostatin receptors: identification of subtype selective peptides and demonstration of high affinity binding of linear peptides. Mol Pharmacol. 43:1993;838-844.
49. Reisine T, Bell G. Molecular biology of somatostatin receptors. Endocr Rev. 16:1995;427-442.
50. Leszczynski D, Zhao Y, Cathapermal S.S, Nilsson J, Foegh M.L. Rat heart smooth muscle cells express high and low affinity receptors for somatostatin-14, which are involved in regulation of cell proliferation. Life Sci. 53:1993;1663-1674.
51. Yamada T, Creutzfeldt W, Beglinger C, Chiba T. The effect of somatostatin on cellular proliferation. Gastroenterol Int. 7:1994;13-23.
52. Reisine T, Zhang Y, Sekura R. Pertussis toxin treatment blocks the inhibition of somatostatin and increases the forskolin stimulation of cAMP accumulation and ACTH secretion from mouse anterior pituitary tumor cells. J Pharmacol Exp Ther. 232:1985;275-282.
53. Reisine T, Guild S. Pertussis blocks SRIF inhibition of calcium mobilization and desensitizes SRIF receptors. J Pharmacol Exp Ther. 235:1985;551-557.
54. Tasumi H, Costa M, Schimerlik M, North R. Potassium conductance increased by noradrenaline, opioids, somatostatin, and G-proteins. J Neurosci. 10:1990;1675-1682.
55. Law S.F, Woulfe D, Reisine T. Mini review. Somatostatin receptor activation of cellular effector systems. Cell Signal. 1:1995;1-8.
56. Colas B, Cambillau C, Buscail L, et al. Stimulation of a membrane tyrosine phosphatase activity by somatostatin analogues in rat pancreatic acinar cells. Eur J Biochem. 207:1992;1017-1024.
57. Law S, Yasuda K, Bell GI, Reisine T. Giα3 and Goα selectively associate with the cloned somatostatin receptor subtype SSTR2. J Biol Chem. 268:1993;10721-10727.
58. Mooradian D.L, Fernandes B, Digilio C.A, Lester B.R. Angiopeptin (BIM23014C) inhibits vascular smooth muscle cell migration in vitro through a G-protein-mediated pathway and is associated with inhibition of adenylyl cyclase and cyclic AMP accumulation. J Cardiovasc Pharmacol. 25:1995;611-618.
59. Matsuda T, Motomura N, Oka T. Angiopeptin as a potent inhibitor of myointimal hyperplasia: systemic injection and local administration via impregnation in a biodegradable polymeric gel. ASAIO J. 39:1993;M512-M517.
60. Motomura N, Matsuda T, Oka T. Suppression of myointimal hyperplasia (II): Pharmacological approach using angiopeptin. J Jpn Angiol. 34:1994;87-93.
61. McNamara D.B, Light J.T, Bellan J.A, et al. Angiopeptin enhances recovery of neoendothelial-dependent, acetylcholine-induced relaxation and inhibits intimal hyperplasia following balloon catheter injury in the rabbit aorta. J Vasc Res (Abstr). 29:1992;166-66.
62. Light J.T, Bellan J.A, Chen I.L, et al. Angiopeptin enhances acetylcholine-induced relaxation and inhibits intimal hyperplasia after vascular injury. Am J Physiol. 265:1993;H1265-H1274.
63. Leszczynski D, Josephs M.D, Fournier R.S, Foegh M.L. Angiopeptin, the octapeptide analogue of somatostatin, decreases rat heart endothelial cell adhesiveness for mononuclear cells. Regul Pept. 43:1993;131-140.
64. Miano JM, Tota R.R, Vlasic N, Danishesky K.J, Stemerman M.B. Early proto-oncogene expression in rat aortic smooth muscle cells following endothelial removal. Am J Pathol. 137:1990;761-765.
65. Bauters C, de Groote P, Adamantidis M, et al. Protooncogene expression in rabbit aorta after wall injury: first marker of the cellular process leading to restenosis after angiology? Eur Heart J. 13:1992;556-559.
66. Bauters C, Belle EV, Wernert N, et al. Angiopeptin inhibits oncogene induction in rabbit aorta after balloon denudation. Circulation. 89:1994;2327-2331.
67. Wahlers T, Mügge A, Oppelt P, et al. Coronary vasculopathy following cardiac transplantation and cyclosporine immunosuppression: preventive treatment with angiopeptin, a somatostatin analog. Transplant Proc. 26:1994;2741-2742.
68. Wahlers T, Mügge A, Oppelt P, et al. Preventive treatment of coronary vasculopathy in heart transplantation by inhibition of smooth muscle cell proliferation with angiopeptin. J Heart Lung Transplant. 14:1995;143-150.
69. Scheidt WV, Meiser BM, Gross T, et al. Angiopeptin inhibits coronary intimal proliferation after human cardiac transplantation. Eur Heart J. 16:1995;274-74. (abstr suppl).
70. Meiser BM, Scheidt Wv, Mair H, et al. Short-term angiopeptin treatment significantly reduces intimal proliferation after heart transplantation (HTx). J Heart Lung Transplant. 14:1995;S56. (suppl).
71. Emanuelsson H, Beatt K.J, Bagger J-P, et al. Long-term effects of angiopeptin treatment in coronary angioplasty. Reduction of clinical events but not angiographic restenosis. Circulation. 91:1995;1689-1696.
72. Eriksen U.H, Amtorp O, Bagger J.P, et al. Randomized double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty. Am Heart J. 130:1995;1-8.